The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that work by stimulating the tibial nerve.
Edwards terminated the deal after the Federal Trade Commission moved to block the acquisition due to anticompetitive concerns ...
The company unveiled the appointment alongside news of the departure of its chief commercial officer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback